Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans

Liver International

Volumn 35, Issue 7, 2015, Pages 1853-1861

  Männistö, Ville T ^a   Simonen, Marko ^a   Hyysalo, Jenni ^b   Soininen, Pasi ^a,c   Kangas, Antti J ^a,c   Kaminska, Dorota ^a   Matte, Ananda K ^a   Venesmaa, Sari ^a   Käkelä, Pirjo ^a   Kärjä, Vesa ^a   Arola, Johanna ^d   Gylling, Helena ^a,b   Cederberg, Henna ^a   Kuusisto, Johanna ^a   Laakso, Markku ^a   Yki Järvinen, Hannele ^b   Ala Korpela, Mika ^a,c,e   Pihlajamäki, Jussi ^a,f  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ketone bodies; Lipid oxidation; NASH; Serum NMR analysis; hydroxybutyrate

Indexed keywords

3 HYDROXYBUTYRIC ACID; KETONE BODY; ACAT1 PROTEIN, HUMAN; ACETATE COENZYME A LIGASE; ACETYL COENZYME A ACETYLTRANSFERASE; ACSS2 PROTEIN, HUMAN; BIOLOGICAL MARKER; FATTY ACID; HYDROXYBUTYRATE DEHYDROGENASE; MESSENGER RNA;

AGED; ARTICLE; BARIATRIC SURGERY; BODY MASS; CALORIMETRY; ENZYME CHEMISTRY; FATTY LIVER; FEMALE; GENE EXPRESSION; GENOTYPE; HEPATITIS; HUMAN; KETOGENESIS; LIPID OXIDATION; LIVER BIOPSY; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; METABOLIC SYNDROME X; MOLECULAR WEIGHT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; POPULATION RESEARCH; ADULT; BLOOD; COMPARATIVE STUDY; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SCREENING; LIVER; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PROTON NUCLEAR MAGNETIC RESONANCE;

3-HYDROXYBUTYRIC ACID; ACETATE-COA LIGASE; ACETYL-COA C-ACETYLTRANSFERASE; ADULT; AGED; BIOMARKERS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDROXYBUTYRATE DEHYDROGENASE; KETONE BODIES; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RNA, MESSENGER;

EID: 84931571498     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12769     Document Type: Article

References (41)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
2. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.
3. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
4. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
5. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 2002; 21: 219-23.
6. Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013; 57: 1394-406.
7. Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009; 50: 1827-38.
8. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-51.
9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
10. Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.
11. Nosadini R, Avogaro A, Trevisan R, et al. Acetoacetate and 3-hydroxybutyrate kinetics in obese and insulin-dependent diabetic humans. Am J Physiol 1985; 248: R611-20.
12. Croci I, Byrne NM, Choquette S, et al. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut 2012; 62: 1625-33
13. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-42.
14. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544-50.
15. Kotronen A, Seppälä-Lindroos A, Vehkavaara S, et al. Liver fat and lipid oxidation in humans. Liver Int 2009; 29: 1439-46.
16. Soininen P, Kangas AJ, Wurtz P, et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-5.
17. Hyysalo J, Männistö VT, Zhou Y, et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 2013; 60: 839-46.
18. Mahendran Y, Vangipurapu J, Cederberg H, et al. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9, 398 Finnish men. Diabetes 2013; 62: 3618-26.
19. Pihlajamäki J, Grönlund S, Simonen M, et al. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism 2010; 59: 866-72.
20. Simonen M, Männistö V, Leppänen J, et al. Desmosterol in human nonalcoholic steatohepatitis. Hepatology 2013; 58: 976-82.
21. Stancakova A, Civelek M, Saleem NK, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9, 369 Finnish men. Diabetes 2012; 61: 1895-902.
22. da Rocha EE, Alves VG, da Fonseca RB. Indirect calorimetry: methodology, instruments and clinical application. Curr Opin Clin Nutr Metab Care 2006; 9: 247-56.
23. Inouye M, Kettunen J, Soininen P, et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol 2010; 6: 441.
24. Tukiainen T, Kettunen J, Kangas AJ, et al. Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum Mol Genet 2012; 21: 1444-55.
25. Kettunen J, Tukiainen T, Sarin AP, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012; 44: 269-76.
26. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-96.
27. Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
28. Vangipurapu J, Stancakova A, Pihlajamäki J, et al. Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6, 733 non-diabetic Finnish men. Diabetologia 2011; 54: 563-71.
29. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 545-63.
30. Dasarathy S, Yang Y, McCullough AJ, et al. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2011; 23: 382-8.
31. Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol 2013; 379: 35-42.
32. Vianna CR, Huntgeburth M, Coppari R, et al. Hypomorphic mutation of PGC-1 beta causes mitochondrial dysfunction and liver insulin resistance. Cell Metab 2006; 4: 453-64.
33. Caldwell SH, de Freitas LA, Park SH, et al. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 2009; 49: 1888-95.
34. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-64.
35. Serviddio G, Bellanti F, Tamborra R, et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut 2008; 57: 957-65.
36. Reiniers MJ, van Golen RF, van Gulik TM, Heger M. Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. Antioxid Redox Signal 2014; 21: 1119-42.
37. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 2003; 125: 1246-57.
38. McCuskey RS, Ito Y, Robertson GR, et al. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386-93.
39. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007; 37: 410-5.
40. Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 243-51.
41. Mulholland AJ, Richards WG. Acetyl-CoA enolization in citrate synthase: a quantum mechanical/molecular mechanical (QM/MM) study. Proteins 1997; 27: 9-25.